Summary
Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand, as well as immersive computer-based technologies and immersive therapeutics to promote health, motor function, and cognition under the Real Immersive System brand; and a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and Packing Coil LP brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
History
Penumbra manufactures several medical devices but specializes in the neuro/vascular market and creates devices that help treat aneurysms and ischemic stroke.In 2014, Penumbra launched its Apollo system, a device that “enables minimally invasive removal of deeply seated tissue and fluids in the brain,” allowing for otherwise inoperable blood clots to be removed.In 2015 the company issued an IPO on the NYSE. In 2018 the company acquired 40% of the outstanding shares of virtual reality joint venture MVI Health. In 2017 the company acquired the Italian distributor Crossmed.
Mission
Penumbra, Inc. is a global healthcare company focused on innovative therapies that designs, develops, manufactures and markets innovative devices.
Vision
Our vision is to be the recognized leader in innovative and effective healthcare solutions that improve patient quality of life.
Key Team
Mr. Lambert Shiu (Chief Accounting Officer)
Ms. Johanna Roberts (Exec. VP, Gen. Counsel & Sec.)
Ms. Lynn Rothman (Exec. VP & Chief Bus. Officer)
Mr. Ben Sorci (Exec. VP of Operations)
Mr. Pankaj Tiwari (Exec. VP & Chief Information Officer)
Ms. Jee Hamlyn-Harris (Investor Relations Officer)
Ms. Shruthi Narayan (Director of Marketing - Vascular)
Recognition and Awards
Penumbra has earned numerous awards, including being named one of the World’s 50 Most Innovative Companies by Fast Company in 2018, Top 10 Fastest Growing Companies by Inc. Magazine in 2017, and Top 10 Companies to Watch in 2015 by Fortune Magazine.
References
United States 
